Podcasts about biobright

Adam Marblestone is the CEO of Convergent Research. He is working with a large and growing network of collaborators and advisors to develop a strategic roadmap for future FROs. Outside of CR, he serves on the boards of several non-profits pursuing new methods of funding and organizing scientific research including Norn Group and New Science, and as an interviewer for the Hertz Foundation. Previously, he was a Schmidt Futures Innovation Fellow, a Fellow with the Federation of American Scientists (FAS), a research scientist at Google DeepMind, Chief Strategy Officer of the brain-computer interface company Kernel, a research scientist at MIT, a PhD student in biophysics with George Church and colleagues at Harvard, and a theoretical physics student at Yale. He has also previously helped to start companies like BioBright, and advised foundations such as Open Philanthropy.Session SummaryIn this episode of the Existential Hope Podcast, our guest is Adam Marblestone, CEO of Convergent Research. Adam shares his journey from working on nanotechnology and neuroscience to pioneering a bold new model for scientific work and funding: Focused Research Organizations (FROs). These nonprofit, deep-tech startups are designed to fill critical gaps in science by building the infrastructure needed to accelerate discovery. Tune in to hear how FROs are unlocking innovation, tackling bottlenecks across fields, and inspiring a new approach to advancing humanity's understanding of the world.Full transcript, list of resources, and art piece: https://www.existentialhope.com/podcastsExistential Hope was created to collect positive and possible scenarios for the future so that we can have more people commit to creating a brighter future, and to begin mapping out the main developments and challenges that need to be navigated to reach it. Existential Hope is a Foresight Institute project.Hosted by Allison Duettmann and Beatrice ErkersFollow Us: Twitter | Facebook | LinkedIn | Existential Hope InstagramExplore every word spoken on this podcast through Fathom.fm. Hosted on Acast. See acast.com/privacy for more information.

Read the full transcript here. What are focused research organizations? Which kinds of research projects lend themselves to the FRO model? Researchers in academia frequently complain about the incentive structures around funding and publishing; so how do FROs change those dynamics? Why must FROs be time-limited, especially if they're successful? Who's in charge in an FRO? How does "field-building" help to improve science? What effects might large language models have on science?Adam Marblestone is the CEO of Convergent Research. He's been launching Focused Research Organizations (FROs) such as E11 bio and Cultivarium. He also serves on the boards of several non-profits pursuing new methods of funding and organizing scientific research including Norn Group and New Science. Previously, he was a Schmidt Futures Innovation Fellow, a consultant for the Astera Institute, a Fellow with the Federation of American Scientists (FAS), a research scientist at Google DeepMind, Chief Strategy Officer of the brain-computer interface company Kernel, a research scientist at MIT, a PhD student in biophysics with George Church and colleagues at Harvard, and a theoretical physics student at Yale. He also previously helped to start companies like BioBright and advised foundations such as the Open Philanthropy Project. His work has been recognized with a Technology Review 35 Innovators Under 35 Award (2018), a Fannie and John Hertz Foundation Fellowship (2010), and a Goldwater Scholarship (2008). Learn more about him at adammarblestone.org. [Read more]

In this episode we chat to Charles Fracchia, CEO and Co-Founder of BioBright a bioscience data company driven to make labs faster and smarter. Showing that building out a smart lab isn't the preserve of the roboticists, Biobright hoovers up every drop of experimental data with a view to make science more reproducible. Their product 'DarwinSync' can hook up to you electronic lab notebooks, be searched through voice, and can even help with the analysis and visualisation of lab data. Charles' CV reads like a who's who of science innovation, from his IBM PhD Fellowship in the MIT Media Lab, to working in George Church's lab at the Wyss Institute. He was also an early intern at Ginkgo Bioworks. He's even been named one of 35 Innovators Under 35 by the MIT Technology Review. Relevant articles: All about BioBright Charles' Site A feature in Scientific American on reproducibility Labiotech piece on lab automation

Charles Fracchia is the founder and CEO of BioBright, a company building the smart lab to improve reproducibility in bio-medical research. He is interested in how artificial intelligence, automation and human-computer interfaces can improve the human ability to do research. He completed his bachelors in biology at Imperial College, his masters between the MIT Media Lab and Harvard Medical School. In 2016, Charles was named one of 35 innovators under 35 by the MIT Technology Review. He is the recipient of several awards including IBM PhD fellowships, an Extraordinary Minds fellowship, one of the first Awesome Foundation fellowships and an Amplify Partners fellowship. He is the author of several patents and is actively authoring more in the field of future laboratory tools. Charles has also been involved in obtaining numerous grants and contracts from DARPA, NSF, Google X, Knight Foundation and the Shanghai High Tech Incubator totaling several millions since 2012.

The O’Reilly Hardware Podcast: The merging worlds of software, hardware, and biology.In this new episode of the Hardware Podcast—which features our first discussion focusing specifically on synthetic biology—David Cranor and I talk with Charles Fracchia, an IBM Fellow at the MIT Media Lab and founder of the synthetic biology company BioBright.Discussion points: The blurring of the lines between biology, software development, hardware engineering, and electrical engineering BioBright’s efforts to create hardware and software tools to reinvent the way biology is done in a lab The most prominent market forces in biology today (especially healthcare) How experiments conducted using Arduino or Raspberry Pi devices are impacting synthetic biology Pembient’s synthetic rhino horns This week’s click spirals Studies on the effects of oxytocin Dafen, a Chinese village where copies of artwork are mass-produced Gorgeous Swiss- and Japanese-made calipers. See a brand comparison here. If you’re looking for a good way to pass a long flight, download the PDF versions of the Mitutoyo, TESA/Brown & Sharpe, and Starrett catalogs.

The O’Reilly Hardware Podcast: The merging worlds of software, hardware, and biology.In this new episode of the Hardware Podcast—which features our first discussion focusing specifically on synthetic biology—David Cranor and I talk with Charles Fracchia, an IBM Fellow at the MIT Media Lab and founder of the synthetic biology company BioBright.Discussion points: The blurring of the lines between biology, software development, hardware engineering, and electrical engineering BioBright’s efforts to create hardware and software tools to reinvent the way biology is done in a lab The most prominent market forces in biology today (especially healthcare) How experiments conducted using Arduino or Raspberry Pi devices are impacting synthetic biology Pembient’s synthetic rhino horns This week’s click spirals Studies on the effects of oxytocin Dafen, a Chinese village where copies of artwork are mass-produced Gorgeous Swiss- and Japanese-made calipers. See a brand comparison here. If you’re looking for a good way to pass a long flight, download the PDF versions of the Mitutoyo, TESA/Brown & Sharpe, and Starrett catalogs.

With a burning desire to combine his passions for digital fabrication, biology and computer science, Charles Fracchia came to MIT and Harvard eager to learn. Going to “bio to bits” (gleaning meaningful information from biological data) is something that Charles had never had an opportunity to do at such a high level, and he had high expectations.  “I though: Oh, surely, I'm coming to these awesome labs here in Boston… I'm sure I'll come in and have an awesome dashboard to work with, like the movie Iron Man. I'll have my cell growth rate here, heart rate here… you know… something fantastic.”As it turns out, the technology some of the best labs are using to extract data from biology has – at least in some respects – stayed the safe for half a century. Charles was shocked “Then I'd get this blank look like… well… here's your notebook and your timer.” [ Listen to the Entire Episode ] For More Information, Visit the HUB of Startups / Business in Emerging Technology. From Robotic Limbs to Getting Angel Investment, from Biotech to Intellectual Property: www.TechEmergence.com Interested in the Future of Humanity and the Ramifications of Emerging Tech? Sentient Potential Covers the Ethical Considerations and Future Projections at the Crossroads of Technology and Consciousness: www.SentientPotential.com